Findings seen for transgender, nonbinary, and gender-diverse adults
MONDAY, March 24, 2025 (HealthDay News) — Gender-affirming hormone therapy (GAHT) in primary care is associated with lower rates of moderate-to-severe depressive symptoms in U.S. transgender, nonbinary, and gender-diverse (TGD) adults over four years of follow-up, according to a study published online March 17 in JAMA Network Open.
Sari L. Reisner, Sc.D., from the University of Michigan in Ann Arbor, and colleagues evaluated the use of GAHT delivered in primary care as an intervention for moderate-to-severe depressive symptoms in diverse TGD adult patients. The analysis included 3,592 TGD patients seen at federally qualified community health centers in Boston and New York City from 2016 to 2019.
The researchers found that 18.9 percent of patients were nonbinary. At baseline, 84.5 percent of the individuals were prescribed GAHT and 15.3 percent reported moderate-to-severe depressive symptoms. There was a statistically lower risk for moderate-to-severe depressive symptoms over follow-up for patients prescribed GAHT versus those not prescribed GAHT (adjusted risk ratio, 0.85).
“The findings of this study suggest that integrated GAHT with primary care and low-barrier GAHT access is associated with lower rates of mental health morbidity in TGD patients,” the authors write.
Two authors disclosed ties to McGraw Hill.
AMH Predicts Benefit of Chemo + Endocrine Therapy in Under 55s With Breast Cancer 
Study IDs Gaps in Hereditary Breast Cancer Risk Assessment Before Gender-Affirming Mastectomy 
Body Fat Percentage May Be Better Indicator of Men"s Reproductive Health Than BMI 
Active Combined Oral Contraceptive Pills Linked to Emotional Eating 
GLP-1 Receptor Agonist Use Common in People With Eating Disorders 
Exposure to Ovarian Hormones Linked to Larger Volumes in Brain Regions 
Females With Anorexia Have Disrupted Gastrointestinal Interoception 
Aglatimagene Besadenovec + Valacyclovir Ups DFS in Localized Prostate Cancer 
